Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 4.4% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 638,040 shares of the company’s stock after purchasing an additional 26,810 shares during the period. Pictet Asset Management Holding SA owned approximately 0.20% of Amneal Pharmaceuticals worth $12,887,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of AMRX. GAMMA Investing LLC boosted its stake in shares of Amneal Pharmaceuticals by 54.9% in the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock worth $32,000 after buying an additional 569 shares during the last quarter. Fortitude Family Office LLC raised its position in Amneal Pharmaceuticals by 100.9% during the third quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock valued at $32,000 after acquiring an additional 807 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Amneal Pharmaceuticals during the second quarter valued at approximately $29,000. Sterling Capital Management LLC lifted its holdings in Amneal Pharmaceuticals by 30.3% in the third quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock valued at $71,000 after acquiring an additional 825 shares during the period. Finally, GK Wealth Management LLC acquired a new position in Amneal Pharmaceuticals in the third quarter valued at approximately $103,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 0.0%

Amneal Pharmaceuticals stock opened at $21.70 on Friday. The company has a debt-to-equity ratio of 5.61, a current ratio of 1.87 and a quick ratio of 1.24. The stock has a market capitalization of $6.93 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 2.47 and a beta of 1.24. The business has a 50 day simple moving average of $19.64 and a 200-day simple moving average of $16.07. Amneal Pharmaceuticals, Inc. has a 12 month low of $11.39 and a 12 month high of $22.07.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.03. Amneal Pharmaceuticals had a return on equity of 283.50% and a net margin of 4.17%. The firm had revenue of $862.68 million for the quarter. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of recent analyst reports. Leerink Partners increased their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. UBS Group restated a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 17th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $24.00 price objective on shares of Amneal Pharmaceuticals in a research report on Thursday, October 29th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.